Biotech Values

[oldberkeley]

D. & 10- I appreciate both of your answers.

10, you stated that MNTA did the offering for FOB funding (and perhaps I'm wrongly inferring that you meant solely for that reason) but that idea was directly contradicted today. They are concerned about a Teva approval, and it was one of the reasons.

For a non-scientist like me to get an accurate understanding of immunogenicity, sameness, a reconfiguration of the manufacturing process, encroachment on MNTA's IP, etc. is difficult if not impossible. Even for the experts they seem like thorny problems causing much debate. That was another reason I asked the question.

Thanks for your time.